H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on BioXcel Therapeutics to $10 from $11 and keeps a Buy rating on the shares. The firm adjusted the company’s model to account for last month’s equity financing.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTAI:
- Bioxcel Therapeutics Advances Alzheimer’s Agitation Treatment Trial
- BioXcel Therapeutics announces TRANQUILITY In-Care Phase 3 trial plan
- BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia
- BioXcel Therapeutics announces $25M registered direct offering
- BioXcel Therapeutics Announces $25 Million Registered Direct Offering
